{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T14:02:21Z","timestamp":1783605741160,"version":"3.55.0"},"reference-count":29,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,10,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>Cervical cancer screening laboratory practices may evolve with new terminology and technologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To investigate changes in cervical cytopathology practice resulting from the 2014 Bethesda System updates and screening technologies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>Questionnaires accompanied 2016 and 2017 mailings of the College of American Pathologists PAP Education program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>In 2016, most laboratories surveyed had adopted or were planning to adopt 2014 Bethesda System updates, and the majority (53%; 365 of 689) used an age cutoff of 45 for reporting benign-appearing endometrial cells. However, 51.3% (354 of 690) of laboratories used the term low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion, for cases with indeterminate features, and 44.9% (298 of 664) of laboratories used a 5000-cell cutoff for minimum squamous cellularity for posthysterectomy and posttherapy specimens. Reporting rates for cervical cytology metrics changed very little from 2013 to 2016, and the median ratio of atypical squamous cells to squamous intraepithelial lesion cases was 1.9 for ThinPrep and 1.8 for SurePath preparations. Most laboratories (59.4%; 389 of 655) did not offer stand-alone primary human papillomavirus (HPV) testing in 2017, and primary HPV testing accounted for a low proportion of HPV testing volumes. The Roche Cobas method was the most common platform for HPV primary screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>These questionnaire surveys provide data about the current status of cervical cytology screening, including changes related to the 2014 Bethesda System updates and the adoption of HPV primary screening techniques.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2018-0603-cp","type":"journal-article","created":{"date-parts":[[2019,4,25]],"date-time":"2019-04-25T13:54:10Z","timestamp":1556200450000},"page":"1196-1202","source":"Crossref","is-referenced-by-count":24,"title":["Bethesda 2014 Implementation and Human Papillomavirus Primary Screening: Practices of Laboratories Participating in the College of American Pathologists PAP Education Program"],"prefix":"10.5858","volume":"143","author":[{"given":"Diane Davis","family":"Davey","sequence":"first","affiliation":[{"name":"From the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Dr Davey); the Department of Biostatistics (Ms Souers) and the Surveys Department (Ms Goodrich), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Mody); the Department of Pathology, The George"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhona J.","family":"Souers","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Dr Davey); the Department of Biostatistics (Ms Souers) and the Surveys Department (Ms Goodrich), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Mody); the Department of Pathology, The George"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Goodrich","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Dr Davey); the Department of Biostatistics (Ms Souers) and the Surveys Department (Ms Goodrich), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Mody); the Department of Pathology, The George"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina R.","family":"Mody","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Dr Davey); the Department of Biostatistics (Ms Souers) and the Surveys Department (Ms Goodrich), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Mody); the Department of Pathology, The George"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sana O.","family":"Tabbara","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Dr Davey); the Department of Biostatistics (Ms Souers) and the Surveys Department (Ms Goodrich), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Mody); the Department of Pathology, The George"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine N.","family":"Booth","sequence":"additional","affiliation":[{"name":"From the Department of Clinical Sciences, University of Central Florida College of Medicine, Orlando (Dr Davey); the Department of Biostatistics (Ms Souers) and the Surveys Department (Ms Goodrich), College of American Pathologists, Northfield, Illinois; the Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, Texas (Dr Mody); the Department of Pathology, The George"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3906","published-online":{"date-parts":[[2019,4,25]]},"reference":[{"issue":"1","key":"2020081300272105100_i1543-2165-143-10-1196-b01","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5858\/arpa.2015-0004-CP","article-title":"Trends in cervical cytology screening and reporting practices: results from the College of American Pathologists 2011 PAP Education Supplemental Questionnaire","volume":"140","author":"Crothers","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"9","key":"2020081300272105100_i1543-2165-143-10-1196-b02","first-page":"903","article-title":"Terminology and specimen adequacy in cervicovaginal cytology: the CAP interlaboratory comparison experience","volume":"116","author":"Davey","year":"1992","journal-title":"Arch Pathol Lab Med"},{"issue":"5","key":"2020081300272105100_i1543-2165-143-10-1196-b03","first-page":"440","article-title":"Atypical squamous cells of undetermined significance: current laboratory practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology","volume":"120","author":"Davey","year":"1996","journal-title":"Arch Pathol Lab Med"},{"issue":"2","key":"2020081300272105100_i1543-2165-143-10-1196-b04","doi-asserted-by":"crossref","first-page":"203","DOI":"10.5858\/2000-124-0203-AECASA","article-title":"Atypical epithelial cells and specimen adequacy: current laboratory practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology","volume":"124","author":"Davey","year":"2000","journal-title":"Arch Pathol Lab Med"},{"issue":"11","key":"2020081300272105100_i1543-2165-143-10-1196-b05","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.5858\/2004-128-1224-BIARRP","article-title":"Bethesda 2001 implementation and reporting rates: 2003 practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology","volume":"128","author":"Davey","year":"2004","journal-title":"Arch Pathol Lab Med"},{"issue":"3","key":"2020081300272105100_i1543-2165-143-10-1196-b06","doi-asserted-by":"crossref","first-page":"331","DOI":"10.5858\/134.3.331","article-title":"Practices of participants in the College of American Pathologists Interlaboratory Comparison Program in Cervicovaginal Cytology, 2006","volume":"134","author":"Eversole","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"12","key":"2020081300272105100_i1543-2165-143-10-1196-b07","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.5858\/arpa.2016-0061-CP","article-title":"Human papillomavirus genotyping testing practice in 2014: results of a College of American Pathologists national survey","volume":"140","author":"Zhao","year":"2016","journal-title":"Arch Pathol Lab Med"},{"issue":"10","key":"2020081300272105100_i1543-2165-143-10-1196-b08","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/cncy.21480","article-title":"Primary human papillomavirus screening for cervical cancer in the United States\u2014US Food and Drug Administration approval, clinical trials, and where we are today","volume":"122","author":"Nayar","year":"2014","journal-title":"Cancer Cytopathol"},{"issue":"5","key":"2020081300272105100_i1543-2165-143-10-1196-b09","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncy.21521","article-title":"The Pap test and Bethesda 2014: \u201cThe reports of my demise have been greatly exaggerated\u201d (after a quotation from Mark Twain)","volume":"123","author":"Nayar","year":"2015","journal-title":"Cancer Cytopathol"},{"issue":"10","key":"2020081300272105100_i1543-2165-143-10-1196-b10","first-page":"185","article-title":"Practice bulletin No. 157 summary: cervical cancer screening and prevention","volume":"127","year":"2016","journal-title":"Obstet Gynecol"},{"issue":"4","key":"2020081300272105100_i1543-2165-143-10-1196-b11","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1097\/AOG.0b013e3182883a34","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"121","author":"Massad","year":"2013","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2020081300272105100_i1543-2165-143-10-1196-b12","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3322\/caac.21139","article-title":"American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer","volume":"62","author":"Saslow","year":"2012","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"2020081300272105100_i1543-2165-143-10-1196-b13","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ygyno.2014.12.022","article-title":"Use of primary high risk papillomavirus testing for cervical cancer screening: interim clinical guidance","volume":"136","author":"Huh","year":"2015","journal-title":"Gynecol Oncol"},{"key":"2020081300272105100_i1543-2165-143-10-1196-b14","first-page":"1","article-title":"Specimen adequacy","author":"Birdsong","year":"2015","journal-title":"The Bethesda System for Reporting Cervical Cytology: Definitions, Criteria, and Explanatory Notes. 3rd ed"},{"issue":"2","key":"2020081300272105100_i1543-2165-143-10-1196-b15","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1309\/AJCPM9X5RCZYEQJQ","article-title":"Low-grade squamous intraepithelial lesion\/cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) is a unique category of cytologic abnormality associated with distinctive HPV and histopathologic CIN2+ detection rates","volume":"141","author":"Barron","year":"2014","journal-title":"Am J Clin Pathol"},{"issue":"5","key":"2020081300272105100_i1543-2165-143-10-1196-b16","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/cncr.11721","article-title":"The significance of the Papanicolaou smear diagnosis of low-grade squamous intraepithelial lesion cannot exclude high-grade squamous intraepithelial lesion","volume":"99","author":"Nasser","year":"2003","journal-title":"Cancer"},{"issue":"2","key":"2020081300272105100_i1543-2165-143-10-1196-b17","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1309\/AJCP8J4ROAVWOSHQ","article-title":"Low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion: a category with an increased outcome of high-grade lesions: use as a quality assurance measure","volume":"138","author":"Nishino","year":"2012","journal-title":"Am J Clin Pathol"},{"issue":"3","key":"2020081300272105100_i1543-2165-143-10-1196-b18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1309\/QRDNMWWAKJQTVJGF","article-title":"\u201cLow-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion\u201d is a distinct cytologic category: histologic outcomes and HPV prevalence","volume":"128","author":"Owens","year":"2007","journal-title":"Am J Clin Pathol"},{"issue":"2","key":"2020081300272105100_i1543-2165-143-10-1196-b19","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1002\/cncy.21346","article-title":"Evidence for increasing usage of low-grade squamous intraepithelial lesion, cannot exclude high-grade squamous intraepithelial lesion (LSIL-H) Pap test interpretations","volume":"122","author":"Walavalkar","year":"2014","journal-title":"Cancer Cytopathol"},{"issue":"11","key":"2020081300272105100_i1543-2165-143-10-1196-b20","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/dc.22990","article-title":"The impact of LSIL-H terminology on patient follow-up patterns: a comparison with LSIL and ASC-H","volume":"41","author":"Thrall","year":"2013","journal-title":"Diagn Cytopathol"},{"key":"2020081300272105100_i1543-2165-143-10-1196-b21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jasc.2018.09.002","article-title":"Age cut-off for reporting benign-appearing endometrial cells in Papanicolaou specimens; should it be raised?: a 10-year retrospective study from a large community hospital","author":"Hinson","year":"2018","journal-title":"J Am Soc Cytopathol"},{"key":"2020081300272105100_i1543-2165-143-10-1196-b22","unstructured":"College of American Pathologists. Cytopathology checklist. 2017 ed. Northfield, IL; College of American Pathologists: 2017. www.cap.org. Accessed August 15, 2018."},{"key":"2020081300272105100_i1543-2165-143-10-1196-b23","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/1741-7015-11-227","article-title":"Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study","volume":"11","author":"Gertig","year":"2013","journal-title":"BMC Med"},{"issue":"33","key":"2020081300272105100_i1543-2165-143-10-1196-b24","first-page":"850","article-title":"National, regional, state and selected local area vaccination coverage among adolescents aged 13\u201317 years\u2014United States, 2016","volume":"65","author":"Walker","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"7","key":"2020081300272105100_i1543-2165-143-10-1196-b25","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force recommendation statement","volume":"320","author":"US Preventive Services Task Force","year":"2018","journal-title":"JAMA"},{"key":"2020081300272105100_i1543-2165-143-10-1196-b26","article-title":"BD Onclarity HPV assay [package insert]","year":"2018"},{"issue":"3","key":"2020081300272105100_i1543-2165-143-10-1196-b27","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ygyno.2018.04.007","article-title":"The Onclarity human papillomavirus trial: design, methods, and baseline results","volume":"149","author":"Stoler","year":"2018","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2020081300272105100_i1543-2165-143-10-1196-b28","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ygyno.2014.11.076","article-title":"Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test","volume":"136","author":"Wright","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"2020081300272105100_i1543-2165-143-10-1196-b29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.jasc.2017.12.001","article-title":"Primary HPV cervical cancer screening in the United States: are we ready?","volume":"7","author":"Nayar","year":"2018","journal-title":"J Am Soc Cytopathol"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/143\/10\/1196\/2368152\/arpa_2018-0603-cp.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/meridian.allenpress.com\/aplm\/article-pdf\/143\/10\/1196\/2368152\/arpa_2018-0603-cp.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:35:07Z","timestamp":1764790507000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/143\/10\/article-p1196.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,25]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,4,25]]},"published-print":{"date-parts":[[2019,10,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2018-0603-cp","relation":{},"ISSN":["0003-9985","1543-2165"],"issn-type":[{"value":"0003-9985","type":"print"},{"value":"1543-2165","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,25]]}}}